Table 1 Relevant clinical trials of combination treatment with ICB
From: Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies
Clinical trial (NCT identifier) | Conditions | Treatment | Patients | n | Phase | States |
|---|---|---|---|---|---|---|
NCT02039674 (KEYNOTE-021) | NSCLC | Pembrolizumab + Ipilimumab + Erlotinib + Gefitinib + Paclitaxel + Carboplatin + Bevacizumab + Pemetrexed | Patients with unresectable or metastatic NSCLC | 267 | I/II | Completed |
NCT02143466 (TATTON) | NSCLC | Durvalumab + Osimertinib + Selumetinib + Savolitinib | NSCLC patients with progression after EGFR-TKIs, T790M positive | 344 | I | Active, not recruiting |
NCT02366143 (IMpower150) | NSCLC | Atezolizumab + Bevacizumab + Paclitaxel + Carboplatin | Chemotherapy-naïve patients with stage IV non-squamous NSCLC | 1202 | III | Completed |
NCT02454933 (CAURAL) | NSCLC | Durvalumab + Osimertinib | NSCLC patients with progression after EGFR-TKIs, T790M positive | 344 | I | Active, not recruiting |
NCT02574078 (CheckMate 370) | NSCLC | Nivolumab + Erlotinib + Crizotinib + Bevacizumab + Pemetrexed + Nab-Paclitaxel + Paclitaxel + Docetaxel + Gemcitabine + Carboplatin | Patients with advanced NSCLC | 341 | I/II | Completed |
NCT02578680 (KEYNOTE-189) | NSCLC | Pembrolizumab + Cisplatin + Carboplatin + Pemetrexed + Dexamethasone | Patients with metastatic non-squamous NSCLC | 616 | III | Active, not recruiting |
NCT02659059 (CheckMate 568) | NSCLC | Nivolumab + Ipilimumab + Platinum doublet chemotherapy | Stage IV NSCLC | 324 | II | Active, not recruiting |
NCT02775435 (KEYNOTE-407) | NSCLC | Pembrolizumab + Paclitaxel+ Nab-paclitaxel + Carboplatin | Patients with metastatic non-squamous NSCLC | 559 | III | Active, not recruiting |
NCT02872116 (CheckMate649) | Gastric cancer GEJ cancer | Nivolumab + Ipilimumab + Oxaliplatin + Capecitabine + Leucovorin + Fluorouracil | Patients with previously untreated advanced or metastatic gastric or GEJ cancer | 2031 | III | Active, not recruiting |
NCT03434379 (IMbrave150) | HCC | Atezolizumab + Bevacizumab + Sorafenib | Patients with locally advanced or metastatic HCC with no prior systemic treatment | 558 | III | Active, not recruiting |
NCT03615326 (MK-3475-811/KEYNOTE-811) | Gastric neoplasms GEJ adenocarcinoma | Pembrolizumab + Cisplatin + 5-FU + Oxaliplatin + Capecitabine + S-1 + Trastuzumab | HER2 + patients with advanced gastric or GEJ adenocarcinoma | 732 | III | Active, not recruiting |
NCT03924050 | NSCLC | Toripalimab + standard chemotherapy | Advanced NSCLC patients with TKI-resistant EGFR-mutated tumors | 350 | III | Unknown |
